Eurofins Scientific SEERFSF +3.01%79 PEG Ratio is 22.11 as of Jun. 27, 2026, which is 1758% above its 10-year median of 1.19. GuruFocus rates ERFSF with a GF Score™ of 79/100 and a GF Value™ of $75.93 (Fairly Valued). The stock has 7 warning signs investors should review. Among 36 Medical Diagnostics & Research companies, Eurofins Scientific SE ranks worse than 97.22% on this metric.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Eurofins Scientific SE's PEG Ratio or its related term are showing as below:
ERFSF'
s PEG Ratio Range Over the Past 10 Years
Min: 0.45 Med: 1.19 Max: 22.67
Current: 22.11
During the past 13 years, Eurofins Scientific SE's highest PEG Ratio was 22.67. The lowest was 0.45. And the median was 1.19.
ERFSF's PEG Ratio is ranked worse than 97.22% of 36
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.28
vs ERFSF: 22.11
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Eurofins Scientific SE (OTCPK:ERFSF) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Eurofins Scientific SE's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eurofins Scientific SE PEG Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Eurofins Scientific SE's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Eurofins Scientific SE's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Eurofins Scientific SE (ERFSF) has a PEG Ratio of 22.11 as of Jun. 27, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Eurofins Scientific SE and its competitors. This is 1758% above median its historical median of 1.19. Over the past decade, Eurofins Scientific SE's PEG Ratio has ranged from 0.45 to 22.67. According to the industry distribution chart, Eurofins Scientific SE ranks #35 out of 36 companies in the Medical Diagnostics & Research industry, placing it in the top 97.2%.
Is Eurofins Scientific SE's PEG Ratio too high?
Eurofins Scientific SE's current PEG Ratio of 22.11 is 1758% above median its 10-year median of 1.19. Over the past 10 years, this metric has ranged from a low of 0.45 to a high of 22.67. The Medical Diagnostics & Research industry median PEG Ratio is 2.28. Eurofins Scientific SE's value of 22.11 is 869.7% above this industry median. Based on the distribution chart, Eurofins Scientific SE ranks #35 out of 36 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Eurofins Scientific SE has a GF Score™ of 79/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Eurofins Scientific SE's PEG Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Eurofins Scientific SE ranks #35 out of 36 companies for PEG Ratio. This places Eurofins Scientific SE in the lower half of its industry. The industry median PEG Ratio is 2.28. Eurofins Scientific SE's value of 22.11 is 869.7% above this benchmark. Historically, Eurofins Scientific SE's own PEG Ratio has ranged from 0.45 to 22.67 over the past decade. While the company's 10-year median is 1.19 vs. the industry median of 2.28, Eurofins Scientific SE has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Medical Diagnostics & Research company?
The median PEG Ratio among Medical Diagnostics & Research companies is 2.28, based on 36 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eurofins Scientific SE's current PEG Ratio of 22.11 is 869.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Eurofins Scientific SE and its competitors. For the Medical Diagnostics & Research industry, the median PEG Ratio is 2.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eurofins Scientific SE's current PEG Ratio is 22.11, which is 1758% above median its own 10-year median of 1.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eurofins Scientific SE stock overvalued right now?
Based on GuruFocus' analysis, Eurofins Scientific SE (ERFSF) is currently considered Fairly Valued. The stock's GF Value™ is $75.93, compared to a current price of $79.77 — trading 5.1% above its estimated fair value. The current PEG Ratio is 22.11, which is 1758% above median its 10-year median of 1.19 and 869.7% above the Medical Diagnostics & Research industry median of 2.28. Eurofins Scientific SE's overall GF Score™ is 79/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Eurofins Scientific SE (ERFSF), the current PEG Ratio is 22.11 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eurofins Scientific SE (ERFSF) Overvalued in 2026?
Based on GuruFocus' analysis, Eurofins Scientific SE stock appears to be overvalued.
The current stock price of $79.77 is trading 5.1% above its estimated GF Value™ of $75.93.
GuruFocus considers Eurofins Scientific SE to be Fairly Valued.
Key valuation signals for ERFSF:
PEG Ratio: 22.11 (1758% above median its 10-year median of 1.19)
GF Value™: $75.93 vs. price of $79.77 (5.1% above fair value)
Industry Position: 869.7% above the Medical Diagnostics & Research median (#35 of 36)
No single metric tells the full story. See the ERFSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eurofins, headquartered in Luxembourg, is a decentralized network of life sciences companies that provide various analytical tests and laboratory services. These include tests to evaluate the safety, identity, composition, authenticity, purity, origin, and traceability of various biological substances and products. Eurofins operates over 950 laboratories in 61 countries. Its revenue from Europe, North America, and the rest of the world contributes approximately 50%, 40%, and 10% of total revenue, respectively. Its areas of business activity are food, feed, and environmental testing ("life"), biopharmaceutical services, diagnostic services and products, and consumer and technology products testing, which contribute approximately 40%, 30%, 20%, and 10% respectively.
79GF Score
Get the complete analysis for ERFSF
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ERFSF has been successfully added to your 
